



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on March 17, 2003.

Kelly L. McDow-Dunham
Name of Attorney/Agent
43,787
Registration No.
Signature of Attorney or Agent

612-445
P#6

P&G Case 1448.009US1 (P130)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of :
Davenport et al. : Confirmation No. 6242
Serial No. 10/087,402 : Group Art Unit 1645
Filed March 1, 2002 : Examiner

For Compositions & Methods For Increasing Amino Acid Absorption In Mammals

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents

Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made below in a Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. ☐ 37 C.F.R. §1.97 (b)(1) - U.S. Direct (within 3-months of filing a regular application or converted provisional)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(1), is being filed within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. ☐ 37 C.F.R. §1.97 (b)(2) - Via PCT (within 3 mo. of Nat'l Stage Entry)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(2), is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application. Therefore, no fee is believed to be due.

RECEIVED
MAR 24 2003
TECH CENTER 1600/2900

3. ☒ 37 C.F.R. §1.97 (b)(3) - (>3 mo. after filing direct or nat'l stage entry, but before 1st O.A.)

This information disclosure statement is being submitted under 37 C.F.R. §1.97 (b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter is enclosed to facilitate charging of the fee, if necessary.

THE FOLLOWING IS ADDITIONAL INFORMATION PERTAINING TO (2) OR (3) MARKED WITH AN (X) ABOVE.

(a) ☐ The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that both a copy of the International Search Report and copies of the references cited therein are present in the national stage file. In accordance with MPEP §1893.03(g), it is respectfully requested that the Examiner note the consideration of these references in the first Office Action via the PTO-892 form.

(b) ☐ The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that a copy of the International Search Report is present in the national stage file. Copies of the references cited in that report are enclosed.

(c) ☐ The Notification of Acceptance of this Application Under 35 U.S.C. §371 does not indicate that a copy of the International Search Report and copies of the references cited are present in the national stage file. Copies of the International Search Report and references are attached.

4. ☐ 37 C.F.R. §1.97 (b)(4) - (before the mailing of a first Office Action after the filing of a request for continued examination under §1.114)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(4), is being filed with the Request for Continued Examination (RCE) under 37 C.F.R. §1.114.

5. ☐ Information to be Considered with CPA Filing. This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 CFR 1.53(d).

6. ☐ 37 C.F.R. §1.97(c) with fee payment - (use after 1st Office Action & before Final Office Action or Notice of Allowance)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

☐ (1) Copies of the cited references were previously cited by or submitted to the USPTO in prior application Case No. ____, U.S. Patent Application Serial No. __, filed __. Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of those documents are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d).

OR

☒ (2) Copies of the cited documents are enclosed.

OR

☐ (3) Copies of all said documents, except document No.'s _____, were submitted and considered in parent application U.S. Patent Application Serial No. _____, filed _____. Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of document No.'s _____ are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of document No.'s _____ are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

☐ (4) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.

☐ (5) Applicants also respectfully request the Examiner to consider and make of record the copending applications listed on the attached page.



Additional information is attached.

Respectfully submitted,

By

Kelly L. McDow-Dunham
Attorney or Agent for Applicant(s)
Registration No. 43,787
(513) 622-0159

Date: March 17, 2003

Customer No. 27752

(1448.009US1 (P130) IDS.doc

Please type a plus sign (+) inside this box → [+]

PTO/SB08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

COMPLETE IF KNOWN

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 2

Application Number	10/087,402
Confirmation Number	6242
Filing Date	March 1, 2002
First Named Inventor	Davenport et al.
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	1448.009US1 (P130)

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-4,873,192	10-10-1989	Kunkel	
		US-5,231,020	07-27-1993	Jorgensen et al.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	FOREIGN PATENT DOCUMENT			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
		Adibi, S.A., and E. L. Morse. 1971 Intestinal transport of dipeptides in man: relative importance of hydrolysis and intact absorption. J. Clin. Invest. 50:2266-2275	
		Adibi, S.A. 1977. The oligopeptide transporter (Pept-1) in human intestine: biology and function. Gastroenterology 113:332-340	
		Brandsch, M., V. Ganapathy, and F. H. Leibach. 1995 H(+)-peptide cotransport in Madin-Darby canine kidney cells: expression and calmodulin-dependent regulation. Am. J. Physiol 268:F391-F397	
		Fei, Y.J., Y. Kanai, S. Nussberger, V. Ganapathy, F.H. Leibach, M. F. Romero, S. K. Singh, W. F. Boron, and M. A. Hediger. 1994. Expression cloning of a mammalian protoncoupled oligopeptide transporter. Nature 368:563-566	
		Ferraris, R.P., J. Diamond, and W. W. Kwan. 1988. Dietary regulation of intestinal transport of the dipeptide carnosine. Am. J. Physiol. 255:G143-G150	
		Ganapathy, V., M. Brandsch, and F. H. Leibach. 1994. Intestinal transport of amino acids and peptides. In: Physiology of the Gastrointestinal Tract, Third ed., (Johnson, L.R., ed.), pp. 1773-1794. Raven Press, New York	
		Kilberg, M.S. 1989. Measurement of amino acid transport by hepatocytes in suspension and monolayer culture. Methods Enzym. 173: 564-575	
		Madin, S.H. and N.B. Darby. 1958. Established kidney cell line of normal adult bovine and ovine origin. Proc. Soc. Exp. Biol. 98:574-576.	
EXAMINER			DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → [+]

PTO/SB08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

COMPLETE IF KNOWN

Application Number	10/087,402
Confirmation Number	6242
Filing Date	March 1, 2002
First Named Inventor	Davenport et al.
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	1448.009US1 (P130)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

2 of 2

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Matthews, J.C. 2000. Amino acid and peptide transport systems. In: Farm Animal Metabolism and Nutrition, (J.P.F.D'mello, ed.), pp. 1773-1794. CABI, New York	
		Matthews, J.C., E.A. Wong, P. K. Bender, J. R. Bloomquist, and K. E. Webb, Jr. 1996. Demonstration and characterization of dipeptide transport system activity in sheep omasal epithelium by expression of mRNA in <i>Xenopus laevis</i> oocytes. J. Anim. Sci. 74:1720-1727	
		Newey, H., and D. H. Smith. 1959. The intestinal absorption of some dipeptides. J. Physiol. 145:48-56	
		Ogihara, H., T. Suzuki, Y. Nagamachi, K. Inui, and K. Takata. 1999. Peptide transporter in the rat small intestine: ultrastructural localization and the effect of starvation and administration of amino acids. Histochem. J. 31:169-174	
		Shiraga, T., K. Miyamoto, H. Tanaka, H. Yamamoto, Y. Taketani, K. Morita, I. Tamai, A. Tsuji, and E. Takeda. 1999. Cellular and molecular mechanisms of dietary regulation on rat intestinal H ⁺ /Peptide transporter PepT1. Gastroenterology 116:354-362	
		Terada, T., K. Sawada, M. Irie, H. Saito, Y. Hashimoto, and K. Inui. 2000. Structural requirements for determining the substrate affinity of peptide transporters PEPT1 and PEPT2. Pflugers. Arch. 440:679-684	
		Walker, D., D. T. Thwaites, N. L. Simmons, H. J. Gilbert, and B. H. Hirst. 1998. Substrate upregulation of the human small intestinal peptide transporter, hPepT1. J. Physiol. 507:697-706	
EXAMINER		DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.

1448.009US1 (P130) PT0SB08.doc